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ABSTRACT
Upon HIV-1 infection of a target cell, the viral
reverse transcriptase (RT) copies the genomic RNA
to synthesize the viral DNA. The genomic RNA is
within the incoming HIV-1 core where it is coated
by molecules of nucleocapsid (NC) protein that
chaperones the reverse transcription process.
Indeed, the RT chaperoning properties of NC
extend from the initiation of cDNA synthesis to com-
pletion of the viral DNA. New and effective drugs
against HIV-1 continue to be required, which
prompted us to search for compounds aimed at in-
hibiting NC protein. Here, we report that the NC
chaperoning activity is extensively inhibited in vitro
by small methylated oligoribonucleotides (mODN).
These mODNs were delivered intracellularly using
a cell-penetrating-peptide and found to impede
HIV-1 replication in primary human cells at
nanomolar concentrations. Extensive analysis
showed that viral cDNA synthesis was severely
impaired by mODNs. Partially resistant viruses with
mutations in NC and RT emerged after months of
passaging in cell culture. A HIV-1 molecular clone
(NL4.3) bearing these mutations was found to repli-
cate at high concentrations of mODN, albeit with a
reduced fitness. Small, methylated ODNs such as
mODN-11 appear to be a new type of highly potent
inhibitor of HIV-1.
INTRODUCTION
Once a target cell is infected by the human immunodeﬁ-
ciency virus type 1 (HIV-1), the process of viral DNA
synthesis by reverse transcriptase (RT) initially takes
place within the virion core structure after its entry into
the cytoplasm (1), which then undergoes structural modi-
ﬁcations to become the reverse transcription complex or
RTC (2). The process of reverse transcription, whereby the
single-stranded genomic RNA serves as the template for
the synthesis of the double-stranded viral DNA ﬂanked by
long-terminal repeats (LTRs), is a complex series of reac-
tions that requires obligatory strand annealing and
transfer. The genomic RNA is found within the HIV-1
core structure where it is extensively coated by
about 1500 molecules of the nucleocapsid protein (NC)
(3–6), a C-terminal product of the Gag polyprotein pre-
cursor generated by protease-mediated maturation. NC
has since long been recognized as an essential co-factor
of RT, chaperoning numerous key steps of the reverse
transcription, namely the initiation of cDNA synthesis
and the two obligatory strand transfers (1,4–9). NC is
also a key determinant in genomic RNA packaging and
virus assembly (10,11) and was recently found to exert a
tight control on the timing of reverse transcription, by
halting cDNA synthesis during virus formation (6). In
addition to the currently available drugs targeting the
HIV-1 enzymes RT, protease and integrase, new candidate
anti-HIV-1 drugs and microbicides are in constant
demand due to the emergence of drug resistant strains.
This prompted us to search for compounds aimed at
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chaperoning activity of NC can be extensively inhibited
in vitro by small methylated oligoribonucleotides
(mODN) mimicking the LTR end sequences. These
mODN were delivered intracellularly using a cell-
penetrating peptide (CPP) (14–17) and found to impede
HIV-1 replication in primary human T lymphocytes and
macrophages at concentrations below 1nM. Moreover,
mODN were found to act as microbicides on cell-free
virus. Extensive analysis and time-of-addition assays
showed that the early phase of HIV-1 replication was
severely impaired by mODN, notably viral cDNA synthe-
sis. Viruses partially resistant to mODN emerged after 6
months passaging in cell culture and contained mutations
in NC and RT. A HIV-1 molecular clone (NL4.3) bearing
these mutations was found to replicate in the presence of
100nM mODN, albeit at a reduced rate.
MATERIALS AND METHODS
CPP and ODNs
Peptide. The peptide Pep-2 (KETWFETWFTEWSQ
PKKKRKV-Cya) which is a potent carrier for the
delivery of PNAs through a non-covalent approach
(14,15) was used throughout the experiments.
DNA oligonucleotides. ODNs used for DNA annealing
and strand transfer assays corresponded to the HIV-1
repeated R sequences, in the sense and anti-sense orienta-
tions, previously described in refs. (18,19) (see
Supplementary Data), respectively.
Modiﬁed ODNs. To prepare 20-O-methylated oligo-
nucleotides containing aliphatic amino groups at their
30-end, commercially available 20-O-methylribonucleoside
phosphoramidites and 30-amino-modiﬁer C3 CPG (Glen
Research) were used. The oligonucleotides were
synthesized by the phosphoramidite method on an auto-
matic ABI 394A DNA synthesizer (Applied Biosystems)
and puriﬁed by electrophoresis in a 20% polyacrylamide/
7M urea gel in TBE. The mODN sequences, methylated
on each residue, were as follows:
mODN-11: 20-O-Me-(GGUUUUUGUGU-NH2);
mODN-9: 20-O-Me-(GGUUUUUGU-NH2) (missing the
30 GU); mODN-9U: 20-O-Me-(UUUUGUGUU-NH2);
methylated random ODN: 20-O-Me-(UCUCACAACUC)
ODN TG (non-methylated): GGTTTTTGTGT
In vitro synthesized RNA
RNAs used for the reverse transcription assays were
synthesized as described in refs. (18,19).
HIV-1 NC protein and other viral proteins
HIV-1 NC(1–55), NC(11–55) and NC(12–53) were synthe-
sised and puriﬁed as described in ref. (19). All other retro-
viral NC proteins, RSV NCp12, MuLV NCp10 and FIV
NCp8 were synthesized and puriﬁed as described in
ref. (18–20). NCs were stored in their zinc bound
form and their concentrations determined as described in
ref. (20–22). HIV-1 Tat protein was synthesized as
reported in ref. (18,19).
Peptide synthesis and puriﬁcation
Pep-2 was synthesized by solid phase using
AEDI-expansin resin with a 9050 Pep Synthesizer
(PioneerTM, Applied Biosystems, Foster City, CA)
(Millipore, Wartford, UK) using the Fmoc/tBoc method
and puriﬁed as described (14,15). Pep-2 was N-acetylated
and bears a cysteamide group at the carboxy-terminus
(–NH–CH2–CH2–SH), which is required for efﬁcient
cellular uptake and delivery. Pep-2 was puriﬁed
by RP-HPLC on a C18 column (Interchrom UP5 WOD/
25M Uptispere 300 5 ODB, 250 21.2mm). Electrospray
ionization mass spectra indicated that the peptide was
highly pure.
Cells
Human primary monocytes were obtained from periph-
eral blood mononuclear cells of healthy donors at the
EFS de Lyon. Monocytes were puriﬁed and differentiated
to macrophages and PBLs isolated and activated as
already described (23–25). HeLaP4 cells (containing an
integrated copy of b-galactosidase under the control of
the viral LTR) and 293T cells were maintained in
complete DMEM with 10% FCS. Chronically infected
MOLT/HIV-1NL4-3 cells (26,27), and SUPT1 cells were
maintained in RPMI 1640 with 10% FCS.
Assays for nucleic acid binding, annealing and strand
transfer
(a) Stem–loop destabilization by NC. We used two
labeled ODNs, cTAR carrying 6-carboxyrhodamine
(Rh6G) and a ﬂuorescence quencher 4-((-
4-(dimethylamino)-phenyl)-azo)-benzoic acid
(DABCYL) on the 50- and 30-termini, respectively,
to monitor stem-loop destabilization, and cTAR
labeled with carboxytetramethylrhodamine (TMR)
and carboxyﬂuorescein (Fl) at its 50- and 30-termini,
respectively, for the annealing experiments.
Inhibition of cTAR melting by NC(11–55) was moni-
tored by adding increasing concentrations of mODN
to a mixture of 25nM Rh6G-50-cTAR-30-DABCYL
and 275nM NC(11–55) in 25mM Tris–HCl, 0.2mM
MgCl2 and 30mM NaCl, pH 7.5. Excitation and
emission wavelengths were at 520 and 550nm, re-
spectively. Inhibition of cTAR/dTAR annealing by
NC(11–55) was investigated by monitoring the an-
nealing kinetics of 5nM TMR-50-cTAR-30-Fl with
50nM dTAR, in the presence of a 11-fold molar
excess of NC(11–55) over cTAR and dTAR (28).
The mODNs were added at a concentration of
440nM to the pre-equilibrated mixtures of NC
with either cTAR or dTAR for 5min to ensure
that binding equilibrium was achieved. Then,
cTAR–dTAR hybridization was initiated by manual
mixing of the two solutions and Fl ﬂuorescence (ex-
citation 480nm, emission 520nm) was continuously
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523440 and 96210M
 1cm
 1 were used for cTAR
and the undecanucleotides, respectively. Emission
spectra and kinetic traces were recorded at 20 C
with a Fluorolog spectroﬂuorometer (Jobin Yvon,
Horiba) equipped with a thermostated cell
compartment.
(b) The DNA and RNA binding assays, and the DNA
strand exchange assays in the presence or absence of
mODN-11, mODN-9, mODN-9U or ODN (TG)
were run as reported in ref. (18,19).
(c) Annealing by NCp7(1–71). Tar(+) and 32P-Tar(–)
ODNs (see Supplementary Data) were incubated
(0.03pmol each) in 10ml of buffer A at NC protein
concentrations with or without methylated or
non-methylated ODN as indicated in the ﬁgure
legends. Reactions were performed at 37 C for
5min except for the positive control that was
incubated at 65 C. To stop the reaction and
denature the protein in order to release it from the
32P-ODN, we added 5ml of a solution containing
20% glycerol, 20mM EDTA pH 8.0, 2% SDS,
0.25% bromophenol blue and 0.4mg/ml calf liver
tRNA. Samples were resolved by 8% native PAGE
in 50mM Tris–Borate pH 8.3, 1mM EDTA at 4 C.
Subsequently, gels were autoradiographed and the
amounts of labeled single- and double-stranded
DNA were assessed by PhosphorImaging.
Time-of-addition experiments
MT4 cells were infected with HIV-1 (IIIb) at a multiplicity
of infection (MOI) of 0.5, and the compounds were added
at different time points after infection (0, 1, 2, 3, 4, 5, 6, 7,
8, 24 and 25h). Viral p24 antigen production was
determined at 31h post-infection (HIV-1 p24 core proﬁle
ELISA; duPont, Dreieich, Germany) (see Figure 2,
ordinate values). The reference compounds (DS,
Efavirenz, AZT, an Integrase Strand Transfer Inhibitor
CHI/1043 or Raltegravir and ritonavir) were added at
standardized concentrations corresponding to 100 times
the EC50 value (half maximal effective concentration),
determined at an MOI of 0.01. The mODN-11 in the
form of nanoparticles upon mixing with a 10-fold excess
of Pep-2, was added at 13nM, which is 50–80  its EC50
value.
Lentiviral vector production and puriﬁcation
Production of the HIV-1, HIV-2, the simian immunodeﬁ-
ciency virus type 1 (SIVmac251) and the murine leukemia
virus retroviral vectors was as described in refs (23–25).
HIV-1 production and treatment of virions with mODNs
Supernatant from MOLT/HIV-1 NL4-3 cells was col-
lected, passed through a 0.45mm PVDF ﬁlter and
puriﬁed as described in ref. (27). Wild-type or mutant
HIV-1 viruses were produced by DNA transfection of
293T cells with the NL4-3 plasmid DNA with mutations
in the NC and RT coding sequences. Virus titers were
assessed by RT-test (27) against standards of known
infectivity. For direct drug treatment of virions, HIV-1
particles were mixed in 20ml (10ml of virus+10mlo f2  
mODN solution in PBS) for 20min at 37 C with the
anti-NC inhibitor mODN-11 or mODN-9 complexed
with Pep-2 (1:10) or with the nucleotide analog AZT
(from the AIDS Reagent and Reference Program, NIH,
USA). Then either RT activity of the virions was directly
monitored by in vitro RT-test (27), or they were added to
HeLaP4 cells in 200ml of medium (10  dilution of
mODN) for 1h to allow virus attachment and infection.
The HeLaP4 cells were covered with 1ml more of medium
(60  ﬁnal dilution of mODN) and virus infectivity was
assessed 48h later by coloring the infected cells (26).
Viral infections
For single-round infections with lentiviral vectors,
HeLaP4 cells, macrophages and PBLs were seeded at
10
5 cells/well. PBLs and macrophages were infected at
the second and ﬁfth day post-activation or differentiation,
respectively. Cells were infected at a MOI of 1 (HeLaP4
cells) or 5 (PBLs, macrophages) 1h after drug addition to
the medium. Infection efﬁciency was examined 3–4 days
later by ﬂow cytometry as a function of eGFP expression.
Infections were performed in the presence of either
mODN-11 or mODN-9 complexed with Pep-2 (1:10),
the nucleoside analog zidovudine (AZT) or non-
nucleoside analog nevirapine (provided by the AIDS
Reagent and Reference Program). For productive infec-
tion of PBLs with wild-type NL4-3 HIV-1, activated
lymphocytes were incubated with either one of the inhibi-
tor 1h before being infected at an MOI of 0.5. After 16h,
cells were washed and the medium replaced together with
the inhibitor. PBLs were cultured in the presence of
IL-2. Virus production in the cell medium was detected
by RT tests 12 days post-infection.
PCR and real-time PCR
HeLaP4 cells (5x 10
5) were infected with HIV-1 based LV
at a MOI of 1, 1h after drug addition to the medium. For
PCR, cells were lysed at 3, 6 and 24h post-infection.
Aliquots from the lysates were serially diluted (three
5-fold dilutions were made) and dilution with no signal
saturation upon PCR ampliﬁcation is shown. The follow-
ing set of primers was used (50–30-nt within parentheses
refer to the complete HIV-1 sequence; GenBank accession
no. M38432): full-length (FL) AC37, CACTCC-CAACG
-AAGA-CAAG (nt 9100–9120) and AC38, CAGCA-AG
CCGA-GTCCT-GCGT (nt 699–708), as described in ref.
(24). Quantitative RT–PCR of HIV-1 RNA was per-
formed as described in the Supplementary Data.
Selection of HIV-1 resistant to mODNs and generation
of mutant viruses
The selection of resistant variants was adapted from a
previously described protocol (29). Multiple parallel
virus passaging experiments were performed using the
lymphotropic HIV-1 strain NL4-3. The selection was
initiated by infecting SupT1 lymphocytes at an MOI of
0.1 in 24-well plates. Next, either none or one of the
mODNs was added at an initial concentration of
5588 Nucleic Acids Research, 2011,Vol.39, No. 130.1nM. Cell cultures were monitored daily for the appear-
ance of syncytia. When full-blown syncytia were observed,
virus supernatants were used to initiate the next cell
culture passage on naive SupT1 cells. The mODN concen-
tration was gradually raised in the course of virus passages
from 0.1 to 500nM during a time period of 6 months.
Virus resistance was assessed (by RT test) on naı¨ve
SupT1 cells infected with supernatants from the
passaged viruses in the presence of increasing concentra-
tions of the mODN. HIV-1 RNA was extracted from such
cells where HIV-1 was replicating in the presence of the
highest drug concentration (cells were with a clear
cytopathic effect) as follows: cells were resuspended in
TRIZOL reagent (Invitrogen) and total RNA/DNA was
extracted following the manufacturer’s protocol. RT was
performed using random hexamers and the Super
Script II kit (Invitrogen). PCR was then performed
using the subsequent cDNA and primers corresponding
to the genes of interest. PCR products were then
subcloned in pGEMT Easy vector and unique colonies
were sent for sequencing and genotypic analysis (see
Supplementary Data).
The mutations found in the NC and RT domains were
inserted into HIV-1 pNL4-3. To this end a fragment con-
taining part of the gag and the pol coding sequences was
cloned into a pBluescript vector in which mutations were
inserted, and then cloned back into pNL4-3. Two muta-
genesis procedures were used: the ﬁrst, including three
successive PCR has already been described (30); the
second used a site-directed mutagenesis kit by
StratageneR. To generate the HIV-1 double mutants RT
L100I and K103N by site-directed mutagenesis the follow-
ing oligonucleotides were used: sense 50-CCACATC-CTG
CAGG-GATAAA-AAAGAA-TAAATC-AGTAAC-AG
TAC-TGG-30 and antisense 50-CCAGTA-CTGTTAC-T
GATTTA-TTCTTT-TTTATCCC-TGCA-GGAT-GTG
G-30. Mutations in NC were inserted as exactly described
in ref. (10). The resulting HIV-1 clones were conﬁrmed by
sequencing, viruses were produced in 293T cells by DNA
transfection, and analyzed for infectivity, replication and
mODN resistance in SupT1 cells.
RESULTS
Inhibition of HIV-1 NC chaperone activities by
methylated oligoribonucleotides
Small 20-O-methylated oligoribonucleotides (mODN)
mimicking the LTR end sequences were found to inhibit
the HIV-1 NC chaperone activities in vitro. We ﬁrst
examined NC ability to destabilize the secondary structure
of the viral TAR stem-loop in presence of mODN
(‘Materials and Methods’ section). To that end we used
cTAR carrying Rh6G (6-carboxyrhodamine) and a ﬂuor-
escence quencher DABCYL (4-4-(dimethylamino)-
phenyl)-azo)-benzoic acid) on the 50- and 30-termini,
respectively. We monitored the Rh6G ﬂuorescence
increase of the doubly labeled Rh6G-50-cTAR
-30-DABCYL stem–loop by the non-aggregating
NC(11–55) peptide, with or without one of the mODN
(see ‘Materials and Methods’ section). Results show that
mODN-11 was very efﬁcient in inhibiting NC-directed
TAR destabilization in vitro (data not shown), most
probably by binding NC protein (Supplementary
Figure 1).
Next, NC-directed annealing of complementary TAR+
TAR– sequences was monitored in a real-time manner
using cTAR labeled with TMR and Fl at its 50- and
30-termini, respectively (TMR-50-cTAR-30-Fl) and its com-
plementary counterpart dTAR (Figure 1A; see inset for
explanation). We found that mODN-11 (with a 20-O-
methyl at each residue) was a potent inhibitor of NCp7
annealing activity (Figure 1) by binding to NC (see below
and Supplementary Figure S1). In fact, ﬂuorescence in-
creases, due to the increase of the interchromophore
distance subsequent to the formation of the cTAR/
dTAR extended duplex (ED), is accelerated  10
4 times
by NC (Figure 1A, inset). However, addition of
mODN-11 at a mODN to NC ratio of 0.75:1 drastically
slowed down cTAR/dTAR annealing by NC (Figure 1A
and B). The non-methylated DNA counterpart (GT) of
mODN-11 appeared far less efﬁcient, indicating that
methylation of the sugars is important for inhibition
(Figure 1A). Last, mODN-9U, missing the 50 GGU of
mODN-11, and mODN-9 missing the 30GU of
mODN-11 and the random methylated sequence had
little inhibitory effect on NC-directed annealing of
cTAR/dTAR, indicating some sequence speciﬁcity in
the mODN inhibition observed. These results are in
agreement with the fact that the NC Zinc Fingers (ZF)
have a preference for GU in vitro (31–34) and indicate
that mODN-11 inhibits the NC chaperoning
activity (Figure 1), most probably by binding to the
protein. In fact, binding of mODN-11 to NC was
demonstrated by titration curves (Supplementary Data
and Supplementary Figure S1), where the binding of
mODN-11 to NC(11–55) was monitored through the
ﬂuorescence quenching of the Trp37 residue (32,34).
Fitting of the titration curves yielded a binding constant
of 1.4±0.1 10e7 M
 1.
The inﬂuence of mODN on NC chaperoning activities
was also investigated using the full-length aggregating
NCp7 protein and in vitro canonical assays namely
TAR:cTAR hybridization, and viral DNA strand
exchange (9,18,19,35,36). Results in Supplementary
Figure S2 show that mODN-11 inhibited NCp7 annealing
activity, while mODN-9 (missing the 30 GU of mODN-11)
was moderately active and the mODN-9U (missing the
50GGU of mODN-11) and the non-methylated ODN
were poorly active. The DNA strand exchange assay
based on R sequences (Figure 1B, top and
Supplementary Data) conﬁrmed that mODN-11 was
capable of inhibiting NC chaperoning activity, while
mODN-9U and ODN-11 were poorly active (Figure 1).
HIV-1 NC is also known to control the speciﬁcity of
reverse transcription by preventing false initiation
in vitro (5–7,37). In the presence of mODN-11, false initi-
ation of reverse transcription was restored, indicating an
inhibition of NCp7 activity with little or no inﬂuence on
the RT enzyme (data not shown). The same chaperoning
assays were conducted with other nucleic acid chaperone
proteins such as HIV-1 Tat, RSV NCp12, MoMuLV
Nucleic Acids Research, 2011,Vol.39, No. 13 5589NCp10 and FIV NCp8 (19–22,37). None of these nucleic
acid chaperone proteins were inhibited by mODN-11 and
mODN-9 (data not shown).
Inhibition of HIV-1 replication by methylated ODNs
The seemingly HIV-1-speciﬁc nature of mODN, notably
the presence of GU sequences and 20-O-methyl, prompted
us to examine their inﬂuence on HIV-1 replication in
human cells. To that end, mODNs were formulated with
a CPP at an ODN to CPP ratio of 1:10 as described in
refs. (14,15), which generates nanoparticles ensuring direct
delivery of the active compound into the cytoplasm of the
target cells. First, we determined the IC50 (half maximal
inhibitory concentration) and CC50 (half maximal cyto-
toxicity concentration) of the formulated mODNs on
HIV-1 replication in MT4 cells, which showed that
mODN-11 strongly inhibited HIV-1 replication with an
IC50 of  0.3nM, while mODN-9 was 100 times less efﬁ-
cient. The CC50 of mODN-11 and mODN-9 was between
7.7 and 13.4mM and thus a 1000-fold higher than the IC50
for mODN-11 formulated with Pep-2 (see ‘Materials and
Methods’ section). Under these conditions the IC50 and
CC50 of AZT were 4.5nM and 50mM, respectively (data
not shown). We then investigated the mode of action of
mODN-11 by means of time of addition assays on MT4
cells infected by HIV-1 as described in ref. (38). Results
revealed that mODN-11 inhibited the early steps in a
manner very similar to the nucleoside analog AZT
(Figure 2).
This prompted us to use a HIV-1-based lentivector
encoding eGFP to infect human HeLa P4 cells with or
without AZT as a control nucleoside RT inhibitor
(NRTI). Inhibition of HeLa P4 cell infection at 1nM
ODN was  90% for mODN-11, 25% for mODN-9 and
10% for mODN-9U (Supplementary Figure S3). The
mODN alone, ODN (TG) or the CPP alone did not
have any effect on lentiviral infection (data not shown).
Thus we focused our analysis on the impact of mODN-11
and mODN-9 on HIV-1 replication in primary human
cells. Primary PBL and macrophages were infected with
the HIV-1-based lentivector, and 60 and 30% inhibition of
Figure 1. In vitro mODN-mediated inhibition of NC nucleic acids chaperoning activity. (A) Inhibitory activity of mODN and related oligonucleo-
tides on NC(11–55)-directed cTAR–dTAR hybridization. The annealing kinetics were performed with 5nM TMR-50-cTAR-30-Fl, 50nM dTAR and
605nM NC(11–55) in the absence (red) or in the presence of 440nM of the random methylated sequence (black), mODN-9U (green), mODN-9
(pink), ODN GT (light blue) and mODN-11 (dark blue) (see ‘Materials and Methods’ section). The orange curve represents the annealing of
TMR-50-cTAR-30-Fl with dTAR in the absence of NC(11–55). Formation of the extended cTAR/dTAR duplex was monitored in real time by Fl
ﬂuorescence (excitation at 480nm and emission at 520nm). Inset: principle of the FRET-based hybridization assay: in green the donor dye (ﬂuor-
escein), and in magenta, the acceptor dye (TMR). Note that the random methylated ODN had no effect while mODN-11 had the strongest inhibitory
activity. (B) The inhibitory activity of the mODNs and a related non-methylated ODN on NCp7(1–71)-directed HIV-1 DNA strand transfer was
investigated in vitro using 32P-labeled R+, mutated R– and wt R– (see Scheme and Supplementary Data), in conditions previously reported (see
‘Materials and Methods’ section). The assays contained 10nM R+:R– mut and 10 nM wt R–, 100nM NCp7(1–71) and increasing concentrations of
the mODN from 100 to 300nM. After 5min at 37 C, samples were processed and analyzed by native PAGE as reported before (18,19). Upper panel:
schematic illustration of the DNA strand transfer reaction, namely formation of the ds DNA R+:R– mut bearing mutations, and subsequently
addition of the wt R– (green) and NCp7 resulting in the formation of the complete R+:R– DNA. Lower panel: quantitative data of the DNA strand
transfer assays with extensive strand transfer (wt NC), inactive NC (Mut NC) and partial strand transfer by heating for 1h at 65 C (Ct T). The
mODN-11 caused extensive inhibition while mODN-9 was partially inhibitory while the non-methylated ODN (TG) was inactive. Note that mODN
complexed with Pep-2 were inactive in such in vitro annealing assays (data not shown). Sequences of the ODNs were as follows: mODN-11, 20-O-Me-
(GGUUUUUGUGU-NH2); mODN-9, 20-O-Me-(GGUUUUUGU-NH2), thus missing the 30 GU; mODN-9U, 20-O-Me-(UUUUGUGUU-NH2);
methylated random ODN: 20-O-Me-(UCUCACAACUC); ODN TG (non-methylated): GGTTTTTGTGT.
5590 Nucleic Acids Research, 2011,Vol.39, No. 13infection was achieved at 1nM mODN-11 and mODN-9,
respectively, while there was  60% inhibition by 10mM
AZT (Figure 3A). In the case of PBLs, mODN-11 was
again more active than mODN-9 with 70 and 50% inhib-
ition, respectively, of lentivector infection at 1nM while
inhibition was 80% at 10mM AZT (Figure 3B). Next, we
examined the impact of mODN on the complete HIV-1
replication in PBLs, since these represent the primary
target cells for HIV-1. The mODNs resulted in extensive
inhibition of virus replication, with 90 and 50% inhibition
for mODN-11 and mODN-9, respectively, at 0.2nM,
while AZT concentrations of 0.2–0.5mM were required
to reach a similar inhibition (Figure 3C).
To investigate the impact of mODN on the infectivity of
cell-free virus, HIV-1 particles were mixed for 20min with
mODN-11 or mODN-9 complexed with Pep-2, or with
AZT in 20ml ﬁnal volume which was then added (and
subsequently the mODN or AZT concentration was
highly diluted) in the medium on HeLaP4 indicator cells.
Virus infectivity was assessed 48h later by counting the
blue (infected) cells upon staining (see ‘Materials and
Methods’ section). Results showed that 15nM
mODN-11 almost completely blocked virus infection
while mODN-9 partially inhibited HIV-1 infection
(60%) (Figure 3D). This was likely due to an inhibition
of cDNA synthesis supported by the fact that exogenous
RT activity from mODN-11 treated virions was signiﬁ-
cantly decreased in vitro (Supplementary Figure S4). The
effect of mODNs on puriﬁed virions may be related to
their capacity to enter viral cores and tightly bind the
RT complex as suggested for other anti-RT inhibitors
(39) and which is consistent with the in vitro data pre-
sented above.
The virus speciﬁcity of the formulated mODN-11 and
mODN-9 was examined on recombinant HIV-2, SIVmac
and MoMuLV infectivity in cell cultures. We found that
infection of these retroviruses was not inﬂuenced by the
mODNs while it was inhibited by AZT (Supplementary
Figure S5).
Inhibition of cDNA synthesis by mODN
Since mODN-mediated inhibition of HIV-1 replication
resembled that caused by AZT (Figure 2), we monitored
cDNA synthesis at 3, 6 and 24h post-infection in the
presence of increasing concentrations of either
mODN-11, mODN-9, mODN-9U or the NRTI AZT at
10mM. Results show that mODN-11 caused an 80–90%
inhibition of cDNA synthesis at 1–5nM at 6–24h, while
mODN-9 and mODN-9U were much less inhibitory. AZT
at 10mM caused an 80–90% reduction (Figure 4;
Supplementary Figure S6A). At the same time, the levels
of genomic RNA in newly infected cells were not affected
by mODN or AZT (Supplementary Figure S6B). Taken
together these results indicate that mODNs target the
reverse transcription of genomic RNA at the early stage
of virus multiplication. This is in agreement with the time
of addition assay where inhibition occurred if AZT was
added 2h post-infection.
HIV-1 resistance to mODN
In an attempt to identify the targets of mODN directed
inhibition of virus replication, selection experiments were
carried out using the HIV-1 strain NL4-3 and SupT1
lymphocytes in the absence of mODN or in the presence
of mODN-11 or mODN-9 at an initial concentration of
0.1nM. Parallel cell cultures, with or without mODN,
Figure 2. Time-of-addition assays. MT-4 cells were infected with HIV-1(IIIB) at an MOI of 0.5, and the test compounds were added at different
times post infection (see ‘Materials and Methods’ section). Viral p24 antigen production was determined at 31h post infection (log p24). Compounds
used were DS 10000 (15mg/ml), Efavirenz (5mg/ml), AZT (0.4mM), Raltegravir (1mM), Ritonavir (2.5mg/ml) and mODN-11 (13nM). The results are
from a representative experiment that was repeated at least once. The antiviral drugs DS 10000 (grey) targeting entry, mODN-11 (red), the NRTI
AZT (black), the NNRTI Efavirenz (yellow), the anti-IN Raltegravir (blue) and the anti-PR Ritonavir (orange) were added individually at the
indicated time points. Results show that mODN-11 inhibited HIV-1 replication in MT4 cells in manner very similar to AZT (red and black,
respectively) and earlier than Efavirenz (yellow).
Nucleic Acids Research, 2011,Vol.39, No. 13 5591Figure 3. Inhibition of HIV-1 replication by mODNs. (A and B) Cell infection by HIV-1 lentivector. Monocyte-derived macrophages (A), and
activated peripheral blood lymphocytes (PBL) (B) were incubated with mODN-11 and mODN-9 at 1–15nM, or with 10mM AZT (as a control), 1h
prior to infection with an HIV-1-based lentiviral vector, pseudotyped with the VSVg envelope and expressing the GFP ﬂuroescent protein (see
‘Materials and Methods’ section). Note that mODN had to be complexed with Pep2 since they were totally inactive in their free form (not shown).
After 72h post-infection, transduction efﬁciencies were assessed by ﬂow cytometry as a function of GFP expression. GFP expression in the absence
of drugs was considered as 100%. Note that mODN-11 was more inhibitory (95% inhibition at 5nM) than mODN-9 on PBL (B), while both
inhibited macrophage infection to similar levels (80% at 5nM) (A) (C) HIV-1 replication in PBLs. Cells were PHA/IL-2 activated for 48h and then
infected with HIV-1 NL4-3 at an MOI of 0.5 1h after addition of mODN-11, mODN-9 or AZT (see ‘Materials and Methods’ section). After 14h,
the cells were extensively washed, medium was replaced, drugs re-administered and cells incubated for 12 days to allow de novo virus production. The
latter was analyzed by monitoring RT-activity of cell-free virions. Viral particles released in the absence of drug were considered as 100%. In the
present experimental conditions, mODN-11 and AZT at 0.5nM and 0.5mM, respectively, were found to extensively inhibit virus production.
(D) Incubation of HIV-1 virions with mODN. Virus pellets of HIV-1 NL4-3 were incubated with mODN (1, 5 and 15nM) and AZT (10mM)
for 20min at 37 C, and used to infect indicator HeLaP4 cells expressing b-galactosidase upon HIV-1 infection. The number of positively infected
blue cells were counted and referred to as 100% for the positive cells infected with untreated virus. RT activity was directly assessed on the virions
incubated with mODN or AZT for 20min at 37 C using the RT-test (cf. ‘Materials and Methods’ section).
Figure 4. Inﬂuence of mODNs on reverse transcription. To evaluate the effect of the mODNs on HIV-1 replication, proviral DNA synthesis was
examined at different times post-infection by PCR. HeLaP4 cells were grown in the presence of AZT, mODN-11, mODN-9 or mODN-9U for 1h
and then infected with HIV-1 LV. At 3, 6 and 24h post-infection, the cells were lysed and PCR was performed to evaluate the complete cDNA (after
the second-strand transfer, see ‘Materials and Methods’ section). The negative control (ct–) represents cells, which were not infected and untreated,
whereas the positive control (ct+) represents infected but untreated cells. Note that mODN-11 was clearly more inhibitory than mODN-9 and
mODN-9U (see lane 5nM).
5592 Nucleic Acids Research, 2011,Vol.39, No. 13were monitored daily for the appearance of syncytia.
When full-blown syncytia were observed, virus super-
natants were used to initiate the next cell culture passage
on naive SupT1 cells. The mODN concentration was grad-
ually raised in the course of the passages from 0.1 to
500nM during a time period of 6 months. The virus re-
sistance was assessed by RT activity on naı¨ve SupT1 cells
infected with supernatants from the passages in the
presence or absence of mODN. Viruses passaged at
increasing concentrations of mODN-11 (Figure 5A) or
mODN-9 (Figure 5B) were replicating in concentrations
as high as 100 and 500nM albeit at reduced rate, while
virus passaged without mODN was almost completely in-
hibited at 0.2 and/or 1nM. (Figure 5). Genotypic analysis
of the viral genes was then performed in search for resist-
ance conferring mutations (see ‘Materials and Methods’
section).
Nucleotide characterization of the HIV-1 strains
resistant to mODNs
The genotypic analysis revealed that two mutations were
repeatedly found in the RT sequence. These were L100I
and K103N, corresponding to U>A and A>U, respect-
ively, known to confer a high level of virus resistance to
non-nucleoside RT inhibitors (NNRTI) such as Efavirenz,
Delavirdine and Nevirapine (39–43). Two G>A mutations
(namely, R32K and M46I) were sometimes found in NC,
while notably none were found in the integrase (IN) and
envelope (Env) coding sequences. The two RT mutations
were inserted into HIV-1 NL4.3 by site-directed mutagen-
esis (see ‘Materials and Methods’ section) and the result-
ing HIV-1 mutant was found to replicate in SupT1 cells in
the presence of mODN at concentrations as high as
100nM (Figure 6A and B), but viral ﬁtness was reduced
since replication levels were  30% of the wild-type
Figure 5. Generation of mODN resistant HIV-1 upon multiple virus passages in cell culture. (A and B) HIV-1wt was grown in SupT1 cells in the
absence or presence of rising concentrations of mODN-11 or mODN-9 for 6 months when resistance to high concentrations of mODN occurred as
observed by syncytia formation under the microscope. To validate these observations, supernatants from the resistant and passaged wild-type viruses
were collected and used for de novo infection of naı¨ve SupT1 cells in the presence of the inhibitors. To that end, SupT1 cells were incubated for 1h
with or without mODN and then infected with the same MOI of resistant or wt virus overnight. Cells were extensively washed, mODN re-added and
de novo virus production was assessed after 4 days by RT testing. Panel shows RT activity as cpm (counts per minute) of radioactive dTTP
32P which
is proportional to virus production in the cell supernatant. Note that both passaged viruses were only partially resistant to mODN, with a ﬁtness
reduced by  60–65% (panels A and B).
Figure 6. Replication of a virus clone resistant to mODN-11 and mODN-9. The molecular clone HIV-1 NL4-3 (WT HIV-1) or HIV-1 NL4-3 with
the resistance conferring mutations in RT (RTmutHIV-1) was used to infect SupT1 cells in the presence of increasing concentrations of either
mODN-11 (A) or mODN-9 (B). Fitness of both viruses was also assessed (C): the time course represents the viral replication in SupT1 cells up to 8
days post-infection at the same MOI (referred to the RT activity). Virus replication was monitored by measuring RT activity in the supernatants (see
‘Materials and Methods’ section and legend to Figure 5).
Nucleic Acids Research, 2011,Vol.39, No. 13 5593NL4.3 (Figure 6C). The NC mutations were also inserted
into HIV-1 NL4-3 but did not confer resistance to
mODNs (data not shown). Their insertion into the
HIV-1 NL4-3 clone containing already the two RT muta-
tions did not inﬂuence virus resistance to mODNs or
ﬁtness (data not shown).
DISCUSSION
Taken together, the data presented herein show for the
ﬁrst time that short 20-O-methylated oligoribonucleotides
rich in GU such as mODN-11 can extensively inhibit the
HIV-1 NC chaperoning activities in vitro (Figure 1 and
Supplementary Figure S1). These mODN show a certain
degree of speciﬁcity as indicated by the extensive inhib-
ition of TAR DNA annealing by NCp7 caused by
mODN-11 as compared to mODN-9 and mODN-9U
(Figure 1A and B). The mechanism of mODN-11 action
is mediated by NC binding (Supplementary Figure S1),
notably that of the hydrophobic plateau formed by the
zinc ﬁngers (ZFs) to the single-stranded mODN rich in
GUs (33,34). Thus, mODN-11 would represent a potent
anti-HIV-1 drug targeting the early steps of HIV-1 repli-
cation in PBL and macrophages (Figures 2 and 3A and B).
In fact, the time of additon assays show that mODN-11
inhibits HIV-1 replication in a manner similar to the
NRTI AZT (Figure 2) by impairing viral DNA synthesis
(Figure 4; Supplementary Figure S6) suggesting that it
targets the RTC. Moreover, addition of mODN-11
together with AZT at sub-nanomolar concentrations
results in a complete inhibition of HIV-1 infection,
indicating that mODN-11 targets an element of the RTC
different from AZT, possibly NC as expected from the
in vitro results (Figure 1; Supplementary Figure S7). In
addition, mODN-11 can target cell-free virions by inhibit-
ing their replication (Figure 3D), and thus would represent
a potential microbicide. Upon virus passaging in the
presence of increasing concentrations of mODN-11 or
mODN-9, virus became resistant to the mODN
(Figure 5). Genetic analysis of the emerging mODN-
resistant viruses allowed to characterize mutations in the
RT and NC coding sequences but not in other Gag and
Pol sequences (see ‘Results’ section). Inserting the two
most frequent mutations in RT, in the HIV-1 NL4.3 mo-
lecular clone revealed that these mutations conferred
phenotypic resistance to mODN-11 and mODN-9 at
100nM (Figure 6).
The above in vitro and ex vivo ﬁndings on such modiﬁed
mODNs further support the view that the RT enzyme
cooperates with NC during viral DNA synthesis in
newly infected cells. This is in agreement with prior
in vitro results where NC was found to be an indispensable
partner of the RT enzyme (4,44,45). Furthermore, ex vivo
evidences clearly show that HIV-1 containing ZF muta-
tions disrupting the NC hydrophobic plateau failed to
complete viral DNA synthesis (4,7,44–46). Therefore, it
is tempting to speculate that the NC binding site on RT
encompasses the NNRTI binding pocket, which lies close
to the polymerase primer grip and the polymerase active
site driving cDNA synthesis (47,48), a question that is
presently receiving further attention.
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